Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice (vol 34, pg 563, 2015)

被引：0
|
作者：
Bykerk, Vivian P. [1 ,2 ]
Oestoer, Andrew J. K. [3 ]
Alvaro-Gracia, Jose [4 ]
Pavelka, Karel [5 ]
Roman Ivorra, Jose Andres [6 ]
Graninger, Winfried [7 ]
Bensen, William [8 ]
Nurmohamed, Michael T. [9 ]
Krause, Andreas [10 ]
Bernasconi, Corrado [11 ]
Aassi, Maher [11 ]
Sibilia, Jean [12 ]
机构：
[1] Hosp Special Surg, Inflammatory Arthrit Ctr, New York, NY 10021 USA
[2] Mt Sinai Hosp, Dept Rheumatol, Toronto, ON M5G 1X5, Canada
[3] Univ Cambridge, Cambridge, England
[4] Hosp Univ Princesa, IIS Princesa, Madrid, Spain
[5] Inst Rheumatol, Prague, Czech Republic
[6] Hosp Univ La Fe, Valencia, Spain
[7] Med Univ Graz, Graz, Austria
[8] McMaster Univ, St Josephs Hosp, Hamilton, ON, Canada
[9] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[10] Immanuel Hosp, Berlin, Germany
[11] F Hoffmann La Roche, Basel, Switzerland
[12] CHU Hautepierre, F-67098 Strasbourg, France
来源：
CLINICAL RHEUMATOLOGY | 2015年 / 34卷 / 07期
关键词：
D O I：
10.1007/s10067-015-2932-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1321 / 1321
页数：1
相关论文
共 39 条
  • [21] An open-label extension study of tocilizumab, in combination with disease modifying anti-rheumatic drugs, in patients with Rheumatoid Arthritis
    Hansrajh, V
    Rudolph, R.
    Tikly, M.
    Musenge, E.
    CLINICAL RHEUMATOLOGY, 2013, 32 : S146 - S146
  • [22] Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs
    Takeuchi, Tsutomu
    Matsubara, Tsukasa
    Urata, Yukitomo
    Suematsu, Eiichi
    Ohta, Shuji
    Honjo, Shigeru
    Abe, Tohru
    Yamamoto, Ami
    Miyasaka, Nobuyuki
    MODERN RHEUMATOLOGY, 2014, 24 (05) : 744 - 753
  • [23] EVALUATION OF INHIBITORY FACTOR OF RADIOGRAPHIC PROGRESSION BY IGURATIMOD ADD-ON THERAPY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSES TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Katayama, K.
    Kon, Y.
    Okubo, T.
    Fukai, R.
    Makino, Y.
    Ito, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1405 - 1406
  • [24] Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
    Matthijs S. van der Leeuw
    Paco M. J. Welsing
    Maria J. H. de Hair
    Johannes W. G. Jacobs
    Anne C. A. Marijnissen
    Suzanne P. Linn-Rasker
    Faouzia Fodili
    Reinhard Bos
    Janneke Tekstra
    Jacob M. van Laar
    Trials, 21
  • [25] Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
    van der Leeuw, Matthijs S.
    Welsing, Paco M. J.
    de Hair, Maria J. H.
    Jacobs, Johannes W. G.
    Marijnissen, Anne C. A.
    Linn-Rasker, Suzanne P.
    Fodili, Faouzia
    Bos, Reinhard
    Tekstra, Janneke
    van Laar, Jacob M.
    TRIALS, 2020, 21 (01)
  • [26] A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
    Klareskog, L.
    Gaubitz, M.
    Rodriguez-Valverde, V.
    Malaise, M.
    Dougados, M.
    Wajdula, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) : 1578 - 1584
  • [27] Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis A Multicenter, Phase IIIb Study
    Mysler, Eduardo
    Cardiel, Mario H.
    Xavier, Ricardo M.
    Lopez, Alejandra
    Ramos-Esquivel, Allan
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : S180 - S186
  • [28] Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice
    Taniguchi, Atsuo
    Urano, Wako
    Tanaka, Eiichi
    Furihata, Shiorl
    Kamitsuji, Shigeo
    Inoue, Eisuke
    Yamanaka, Mariko
    Yamanaka, Hisashl
    Kamatani, Naoyuki
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (06): : 383 - 390
  • [29] COMPARISON OF TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH NON-BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO ANTI-TNF AGENTS
    Oestoer, A.
    Roman Ivorra, J. A.
    Wollenhaupt, J.
    Mpofu, C.
    Bernasconi, C.
    Sibilia, J.
    Bykerk, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 372 - 373
  • [30] Comparison of Hand-Wrist Findings of Rheumatoid Arthritis Patients According to the Use of Synthetic and Biological Disease-Modifying Antirheumatic Drugs (DMARDs): A Clinical, Radiographic, and Ultrasonographic Study
    Cinar, Cigdem
    Dogan, Yunus Emre
    Harman, Halil
    Yurttutmus, Zeynep
    Bagatir, Nazire
    Doran, Muhsin
    Ones, Kadriye
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
1234